Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Cotinga Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cotinga Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Cotinga Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Cotinga Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cotinga Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Cotinga Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Cotinga Pharmaceuticals's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Cotinga Pharmaceuticals's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Cotinga Pharmaceuticals is high growth as no earnings estimate data is available.
Unable to determine if Cotinga Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Cotinga Pharmaceuticals's filings and announcements here.
Cotinga Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Cotinga Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Cotinga Pharmaceuticals's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Cotinga Pharmaceuticals has no long term commitments.
This treemap shows a more detailed breakdown of
Cotinga Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Cotinga Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Ms. Alison D. Silva, MA, MS, has been the Chief Executive Officer, President and Consultant of Critical Outcome Technologies Inc. since January 1, 2017, July 5, 2016 and 2013 respectively. Ms. Silva founded Synlogic, Inc. and served as its Executive Vice President and Chief Operating Officer in June 13, 2016. Ms. Silva is a Principal and Co-founder of Orphan Group. She served as a Vice President of Drug Development at Cequent Pharmaceuticals, Inc. Ms. Silva served as a Director of Development at Cequent Pharmaceuticals, Inc. At Cequent, Ms. Silva is responsible for the preclinical development of new therapeutic candidates, manufacturing oversight, regulatory issues and strategic development of the clinical platform and trial design. Ms. Silva served as Chief Operating Officer at SLA Pharma. She was Clinical Trials/Laboratory Manager at Pfizer where she was responsible for pre-approved cardiovascular indicated treatments, dealing primarily with clinical trial management, investigator and site initiation and regulatory/IRB submissions. She was responsible for a team of CRAs, study monitors and study coordinators, interfacing with therapeutic heads for clinical trial design and strategy. Prior to her tenure at Pfizer, Ms. Silva was Laboratory Manager of an infertility department at Massachusetts General Hospital (MGH) and Co-Principal Investigator and Study Head at the Cardiac Catheterization Laboratory of UMass-Worcester. She has been a Non-Independent Director of Critical Outcome Technologies Inc. since May 14, 2015. She served as an Independent Director of Critical Outcome Technologies Inc. since May 14, 2015 until June 16, 2016. Ms. Silva received her undergraduate degree from Clark University and an M.S. degree from UMass Medical Center. She holds a BA in Biology and Mathematics from Clark University and an MS from Clark University and UMass Medical Center.
Alison's compensation has increased whilst company is loss making.
Alison's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Cotinga Pharmaceuticals management team is about average.
CEO, President & Director
Chief Scientific Officer
Chief Financial Officer
Director of Resourcing & Operations
Vice President of Investor Relations
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Cotinga Pharmaceuticals board of directors is about average.
Cotinga Pharmaceuticals Inc., a biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, a clinical stage oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. was founded in 1999 and is based in Boston, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.